agenda: all attendees

Transcription

1 THURSDY, NOVEMBER 9 - STURDY, NOVEMBER 11 SESSIONS B SESSIONS C SESSIONS D SESSIONS Designed for healthcare professionals. CME/CE is provided unless noted otherwise. (*) Designed for recently diagnosed patients and their caregivers. Designed for those who have been living with PF for a while. Designed for individuals who are not currently living with PF, such as transplant recipients and individuals who have lost a loved one. While some sessions are tailored for attendees with specific experiences, you may attend any session that interests you. REGISTRTION 7:30.M. - 8:00 P.M. COMMUNITY PULMONOLOGISTS ND ILD FELLOWS (CME) 10:00.M. - 4:00 P.M. BRODWY J Protocol for evaluation of the patient with interstitial lung disease How to assess for autoimmune disease in your ILD patient Evaluating an occupational exposure history MDD and an accurate diagnosis in ILD How to effectively read an HRCT and utilize its clues for differential diagnosis in ILD pproach to pathological analysis of ILDs Lisa Lancaster, MD ryeh Fisher, MD Mridu Gulati, MD David Lederer, MD Mary Salvatore, MD Joyce Johnson, MD Lunch provided Utility and options for lung biopsy: Emerging utility of bronchoscopic cryobiopsy pproved therapies for IPF: review of the data Safety and management of side effects of pirfenidone and nintedanib Stem-cell and cell-based therapies in lung disease (paucity of data in just IPF) Non-pharmacological management of IPF/ILD Palliative care and hospice Evaluation for lung transplant Fabien Maldonado, MD Sonye Danoff, MD Marilyn Glassberg, MD Kathleen O. Lindell, PhD, RN Tim Whelan, MD 1

2 THURSDY, NOVEMBER 9 PTIENTS ND CREGIVERS: LUNCH TKING N CTIVE ROLE IN YOUR IDIOPTHIC PULMONRY FIBROSIS (IPF) MNGEMENT - PRESENTED BY GENENTECH 11:30.M. 12:45 P.M. CUMBERLND 5 Pre-registration is required and opens at the Summit at 11.M on Thursday. Open to tracks B, C, and D only. PTIENTS ND CREGIVERS: INTRO TO THE PFF, NEED MEETS CTION, ND UNDERSTNDING THE BSICS OF RESERCH 1:00 P.M. 4:00 P.M. BRODWY F Introduction of the PFF and the Care Center Network Research 101: Understanding the process, terminology, and definitions and how a drug is brought to market Q& Break (15 minute) Need Meets ction Part I: Overview of volunteering at the PFF Need Meets ction Part II: Overview of effective fundraising Q& FOCUS GROUPS 1:00 P.M. - 2:00 P.M CUMBERLND 2 & 4 Focus Group 1 (1:00 P.M. - 2:00 P.M.) Focus Group 2 (1:00 P.M. - 2:00 P.M.) FOCUS GROUPS 2:00 P.M. - 5:00 P.M CUMBERLND 2 & 4 Focus Group 3 (2:00 P.M. - 3:00 P.M.) Focus Group 4 (2:00 P.M. - 3:00 P.M.) Focus Group 5 (2:00 P.M. - 3:00 P.M.) WELCOME RECEPTION ND POSTER PRESENTTION: SPONSORED BY HLES FMILY FOUNDTION 5:00 P.M. - 8:00 P.M. PREFUNCTION RE Kevin Flaherty, MD, MS Hal Collard, MD, PFF mbassador, David McNinch ll ll PFF Development Team and Panel Volunteers PFF Development Team and Panel Volunteers ll 2

3 FRIDY, NOVEMBER 10 REGISTRTION 7:00.M. - 8:00 P.M. BREKFST 7:00.M. - 8:00.M. PLENRY SESSION I: PROMISE OF GENETICS ND PERSONLIZED MEDICINE IN PF (CME) 8:00.M. 10:00.M. BRODWY E,F National Heart, Lung and Blood Institute (NHLBI) support for personalized therapy in lung disease State-of-the-art approaches to genetic discovery in complex disease Jim Kiley, PhD Jeff Trent, PhD Current status of clinical genetic testing in ILD genetic counselor s perspective: Impact of genetic information for patients and families Panel discussion 30 minute break and networking ll SESSION 1: ENVIRONMENTL INFLUENCES(CME) 10:30.M. - 12:15 P.M. BRODWY E Poster winner: bstract talk I TB Jim Loyd, MD Janet Talbert, MS, CGC Jim Kiley, Jeff Trent, Jim Loyd, Janet Talbert, Jane Nelson, Heather Kagel The microbiome in IPF Gastroesophageal Reflux Disease (GERD) in ILD Sleep apnea in ILD utoimmune mechanisms of pulmonary fibrosis: CTD-ILD SESSION 1B, C, D: KIDBILLY MUSIC - PRESENTED BY GENENTECH 10:30.M. 12:15 P.M. BRODWY G,H,J Perspectives from ll: Songwriting for team-building, networking, and emotional healing SESSION 2: GENETICS OF ILD (CME) 1:15 P.M. - 2:50 P.M. BRODWY E Poster winner: bstract talk II Spectrum of telomere-related ILD Phil Molyneaux, PhD Ganesh Raghu, MD Lisa Lancaster, MD ryeh Fisher, MD KidBilly Music TB Mary rmanios, MD Progression and outcome of telomere-related ILD * CME credit not provided 3 Christine Garcia, MD

4 FRIDY, NOVEMBER 10 New genes associated with familial ILD Jon Kropski, MD * Results of whole genome sequencing in sporadic IPF Brian Yaspan, PhD SESSION 2B: UNDERSTNDING ILD ND IPF 1:15 P.M. 2:55 P.M. BRODWY K Part I: Overview of ILD, IPF, and connective tissue disease B Kristin Highland, MD Part II: Understanding your test results: HRCT, 6MWT, PFTs, and oximetry Q& SESSION 2C: QULITY OF LIFE: NEXT STEPS 1:15 P.M. - 2:55 P.M. BRODWY G,H Part I: Evaluation for lung transplantation Part II: Using mindfulness for stress management in chronic disease Part III: Treatment of cough Q& SESSION 2D: CLL TO CTION, PRT I 1:15 P.M. 2:50 P.M. BRODWY J Part I: Transitioning after the loss of a loved one, after a transplant (two roundtables) Part II: How to participate in legislative advocacy Group ctivity 30 minute break and networking SESSION 3: DISESE MECHNISMS I (CME) 3:15 P.M. - 4:50 P.M. BRODWY E Poster winner: bstract talk III Pre-clinical modeling of telomerase deficiency Role of aging and senescence in IPF Epithelium as the guardian of the lungs: Response to injury Mechanism of alveolar epithelial cell renewal: Impact on ILD SESSION 3B: OXYGEN THERPY, PULMONRY REHBILITTION, ND SYMPTOM MNGEMENT 3:15 P.M. 4:55 P.M. BRODWY K Mary Beth Scholand, MD ll C Josh Mooney, MD, MS Linda Manning, MD D Kathleen O. Lindell, PhD, RN, John Mulder Bill Schmidt, Kate Gates ll ll Paul Wolters, MD Victor Thannickal, MD Tushar Desai, MD, MPH Paul Noble, MD B 4

5 FRIDY, NOVEMBER 10 Part I: Living with oxygen therapy and PF»» Overview of various types of POCs, compressed gas units, trans-fill systems, and backpacks»» How can I be active and travel with O2 (MedJet and other emergency travel services)? Part II: Pulmonary rehab: What is it and how can it help me? Part III: Symptom management: Cough, dyspnea and fatigue Q& SESSION 3C: WHT S IN THE PIPELINE? CURRENT CLINICL TRILS, POTENTIL THERPIES, ND HOW THE PROCESS WORKS 3:15 P.M. - 4:55 P.M. BRODWY G,H Part I: Understanding how clinical trials work and the therapeutic process to bring a drug to market Part II: Current clinical drug trials in the pipeline for IPF and PF, and an overview of potential therapies moving forward Q& SESSION 3D: CLL TO CTION PRT II: HOW TO HOST FUNDRISING EVENT 3:15 P.M. - 4:55 P.M. BRODWY J How to host a fundraising event Susan Jacobs, RN, M Trina Limberg, BS, RRT Mary Strek, MD ll C Bill Bradford, MD, PhD Gregory Cosgrove, MD ll D PFF Development Team NETWORKING COCKTIL HOUR 5:30 P.M. - 6:30 P.M. PREFUNCTION RE NETWORKING DINNER WITH ENTERTINMENT BY KIDBILLY MUSIC ND THE PFF COMMUNITY, PRESENTED BY GENENTECH 6:30 P.M. - 9:00 P.M. BRODWY E 5

6 STURDY, NOVEMBER 11 REGISTRTION 7:00.M. - 4:00 P.M. BREKFST 7:00.M. - 8:00.M. BRODWY E PLENRY SESSION II: MXIMIZING THE IMPCT OF VILBLE THERPIES IN IPF (CME) 8:00.M. 10:00.M. BRODWY E,F KEYNOTE: Re-thinking clinical trials in PF Gordon R. Bernard, MD PFF Care Center Network and PFF Patient Registry Kevin Flaherty, MD, MS Improving care for PF patients and adherence to treatment plans: physician family member s perspective Jason Martin, MD Gordon R.Bernard, Kevin PNEL DISCUSSION: Opportunities and obstacles to provide optimal care for PF in 2017 Flaherty, Jason Martin, Greg Cosgrove, Maryluz Fuentes, MD, Carolyn dams-duda 30 minute break and networking ll SESSION 4: DIGNOSIS OF IPF (CME) 10:30.M. - 12:15 P.M. BRODWY E Poster winner: bstract talk IV TB dvances in HRCT imaging, quantitative HRCT imaging in IPF trials and clinical care Jonathan Goldin, MD, PhD New approaches to diagnosis: Potential role for cryobiopsy Fabien Maldonado, MD Pre-clinical ILD Lessons from at-risk cohorts SESSION 4B, C, D: BSICS OF GENETICS ND WHT WE KNOW BOUT STEM CELL THERPY 10:30.M. - 12:15 P.M. BRODWY F Part I: Genetics 101 in IPF Part II: Stem cell therapies and biotourism»» What is stem cell therapy and what is it approved for?»» Stem cell centers in the community Part III: Clinical trials with stem cells for ILD Q& Gary M. Hunninghake, MD Tim Blackwell, MD Jim Loyd, MD Sonye Danoff, MD Marilyn Glassberg, MD ll * CME credit not provided 6

7 STURDY, NOVEMBER 11 LUNCH ND NETWORKING (B, C GROUPS) 12:15 P.M. - 1:15 P.M. BRODWY E Lunch with people who live in your region LUNCH ND NETWORKING (D GROUP) 12:15 P.M. - 2:00 P.M. Lunch off-site SESSION 5: THERPEUTICS (CME) 1:15 P.M. - 2:50 P.M. BRODWY E Poster winner: bstract talk V Drug development in IPF: What is on the horizon B C D PFF Staff TB ndy Limper, MD * Stem cell therapies: Real possibility or not? Ramona Doyle, MD Personalized medicine in IPF, integrating genetics in clinical trials Role of biomarkers in diagnosis and treatment SESSION 5B, C: PPROVED THERPIES FOR IPF ND DIGNOSIS ND TRETMENT OF COMORBIDITIES IN ILD 1:15 P.M. - 2:50 P.M. BRODWY F Part I: Overview of pirfenidone and nintedanib Part II: dherence to treatment plans: Safety and management of side effects with pirfenidone and nintedanib Part III: How to qualify for reduced payment plans Imre Noth, MD Naftali Kaminski, MD B C Joyce Lee, MD nne Turner, RN, BSN Breakout Discussions: Diagnosis and Treatment of Comorbidities Obstructive sleep apnea (OS) Gastroesophageal Reflux Disease (GERD) Scleroderma Sarcoidosis SESSION 5D: CLL TO CTION PRT III: WHT S NEXT 2:30 P.M. - 4:00 P.M. BRODWY J Planning for the future Lisa Lancaster, MD Kristin Highland, MD Bob Baughman, MD D PFF Staff FOCUS GROUPS 2:30 P.M. - 3:30 P.M CUMBERLND 2 &4 * CME credit not provided 7

8 STURDY, NOVEMBER 11 Focus group 6 (2:30 P.M. - 3:30 P.M.) Focus group 7 (2:30 P.M. - 3:30 P.M.) BREK ND NETWORKING (GROUPS, B, C) 2:50 P.M. - 3:15 P.M. B C SESSION 6: DISESE MECHNISMS II (CME) 3:15 P.M. - 4:50 P.M. BRODWY E Poster Winner: bstract Talk VI Lessons from other rare genetic diseases - Hermansky-Pudlak Syndrome Mechanoregulation of matric deposition and fibrosis progression Epithelial-fibroblast interactions in lung fibrosis Immune/inflammatory cells in IPF TB Lisa Young Dan Tschumperlin, PhD Kevin Kim, MD Erica Herzog, MD, PhD SESSION 6B, C: ROUNDTBLE DISCUSSIONS 3:15 P.M. - 4:50 P.M. BRODWY F Caregiver burnout How to prepare for an effective clinical visit with your doctor Depression and anxiety in chronic disease Palliative and hospice care How to participate in legislative advocacy B C John Mulder David Lederer, MD, Michele Peters Jim Jackson, PhD Kathleen O. Lindell, PhD, RN Bill Schmidt, Kate Gates 8